According to the World Health Organisation (WHO), the largest single health threat to the population of the world today is antimicrobial resistance (AMR). How can it be countered and what options are open to government regulators, the medical profession and, especially, the pharmaceutical companies for the development of new antibiotics?
These issues were at the heart of a one-day workshop – ‘Best use of medicines legislation to bring new antibiotics to patients and combat the resistance problem’ – at the European Medicines Agency (EMA) in London in November 2013. Participants included regulators, medical bodies, pharmacists’ organisations, patient and healthcare professional groups, reimbursement bodies and the pharmaceutical industry. There was a strong attendance from the US, including representatives of the Food & Drug Administration (FDA), the Infectious Diseases Society of America, and Cubist Pharmaceuticals.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.